Indegene Limited — Quarter ended 31 March 2026 (year ended 31 March 2026)
| Sl. No. | Particulars | Quarter ended 31 March 2026 | Quarter ended 31 December 2025 | Quarter ended 31 March 2025 | Year ended 31 March 2026 | Year ended 31 March 2025 |
|---|---|---|---|---|---|---|
| 1 | Income | |||||
| (a) Revenue from operations | 10,034 | 35,105 | ||||
| (b) Other income (net) | 108 | 720 | ||||
| Total income | 10,142 | 35,825 | ||||
| 2 | Expenses | |||||
| (a) Employee benefits expense | 6,324 | 21,977 | ||||
| (b) Finance costs | 72 | 193 | ||||
| (c) Depreciation and amortisation expense | 418 | 1,264 | ||||
| (d) Other expenses | 2,074 | 6,938 | ||||
| Total expenses | 8,888 | 30,372 | ||||
| 3 | Profit before exceptional item and tax (1-2) | 1,254 | 5,453 | |||
| 4 | Exceptional items (net) (refer note 10) | (203) | (203) | |||
| 5 | Profit before tax (3+4) | 1,051 | 5,250 | |||
| 6 | Tax expense | |||||
| – Current tax | 226 | 1,763 | ||||
| – Deferred tax | 28 | (524) | ||||
| Total tax expense | 254 | 1,239 | ||||
| 7 | Profit for the period/year (5-6) | 797 | 4,011 | |||
| 8 | Total Other Comprehensive Income for the period/year (net of tax) | 550 | 193 | 26 | 1,394 | 256 |
| 9 | Total Comprehensive Income for the period/year (7+8) | 1,347 | 1,222 | 1,202 | 5,405 | 4,323 |
| 10 | Paid-up equity share capital (Face value of ₹ 2 each) | 481 | 480 | 479 | 481 | 479 |
| 11 | Other equity | 30,906 | 25,677 | |||
| 12 | Earnings per equity share (face value of ₹ 2 each) | |||||
| (a) Basic (in ₹) | 3.32 | 4.29 | 4.91 | 16.72 | 17.15 | |
| (b) Diluted (in ₹) | 3.30 | 4.26 | 4.88 | 16.62 | 17.02 |
| Particulars | As at 31 March 2026 (Audited) | As at 31 March 2025 (Audited) |
|---|---|---|
| A ASSETS | ||
| I Non-current assets | ||
| (a) Property, plant and equipment | 586 | 402 |
| (b) Capital work-in-progress | 118 | 36 |
| (c) Right-of-use assets | 1,354 | 947 |
| (d) Goodwill | 11,343 | 3,565 |
| (e) Other intangible assets | 4,833 | 1,862 |
| (f) Financial assets | ||
| (i) Other financial assets | 804 | 133 |
| (g) Deferred tax assets (net) | 768 | 898 |
| (h) Non-current tax assets (net) | 172 | 91 |
| (i) Other non-current assets | 41 | 25 |
| Total non current assets | 20,019 | 7,959 |
| II Current assets | ||
| (a) Financial assets | ||
| (i) Investments | 10,995 | 12,897 |
| (ii) Trade receivables | ||
| – Billed | 7,702 | 6,322 |
| – Unbilled | 2,116 | 1,192 |
| (iii) Cash and cash equivalents | 3,008 | 2,410 |
| (iv) Other bank balances | 811 | 1,336 |
| (v) Other financial assets | 103 | 126 |
| (b) Current tax assets (net) | 65 | – |
| (c) Other current assets | 1,384 | 1,017 |
| Total current assets | 26,184 | 25,300 |
| Total assets | 46,203 | 33,259 |
| B EQUITY AND LIABILITIES | ||
| 1 Equity | ||
| (a) Equity share capital | 481 | 479 |
| (b) Other equity | 30,906 | 25,677 |
| Total equity | 31,387 | 26,156 |
| 2 Liabilities | ||
| I Non-current liabilities | ||
| (a) Financials liabilities | ||
| (i) Lease liabilities | 1,050 | 724 |
| (ii) Other financial liabilities | 2,031 | 149 |
| (b) Provisions | 873 | 585 |
| Total non-current liabilities | 3,954 | 1,458 |
| II Current liabilities | ||
| (a) Financials liabilities | ||
| (i) Lease liabilities | 394 | 292 |
| (ii) Trade payables | ||
| – Total outstanding dues of micro enterprises and small enterprises | 26 | 17 |
| – Total outstanding dues of creditors other than micro enterprises and small enterprises | 1,781 | 917 |
| (iii) Other financial liabilities | 3,055 | 1,151 |
| (b) Other current liabilities | 4,325 | 2,510 |
| (c) Provisions | 798 | 677 |
| (d) Current tax liabilities (net) | 483 | 81 |
| Total current liabilities | 10,862 | 5,645 |
| Total liabilities | 14,816 | 7,103 |
| Total equity and liabilities | 46,203 | 33,259 |
| Particulars | Year ended 31 March 2026 Audited | Year ended 31 March 2025 Audited |
|---|---|---|
| A. Cash flows from operating activities | ||
| Profit before tax for the period | 5,250 | 5,393 |
| Adjustments to reconcile profit for the year to net cash generated from operating activities: | ||
| Depreciation and amortisation expense | 1,265 | 802 |
| Finance costs | 159 | 194 |
| Gain due to change in contingent consideration | – | (162) |
| Exceptional items – Provision for litigation expenses | 203 | – |
| Interest income and dividend income | (363) | (501) |
| Loss allowance on loan | – | 135 |
| Net gain on disposal / fair valuation of investments | (300) | (292) |
| Gain on termination of lease | (9) | – |
| Loss on sale of fixed assets | (1) | – |
| Bad debts written off | 8 | – |
| Expected credit loss provision / (reversal) on trade receivables and advances | – | 18 |
| Equity settled share based payment expense | 256 | 174 |
| Effect of exchange loss / (gain) on restatement | 54 | 17 |
| Operating profit before working capital changes | 6,522 | 5,778 |
| Movements in working capital: | ||
| (Increase)/decrease in trade receivables | 35 | (820) |
| (Increase)/ decrease in loans and advances and other assets | (231) | 343 |
| Increase in liabilities | 1,437 | 611 |
| Increase in provisions | 221 | 107 |
| Cash generated from operating activities | 7,984 | 6,019 |
| Income tax paid (net) | (1,476) | (1,600) |
| Net cash generated from operating activities (A) | 6,508 | 4,419 |
| B. Cash flows from investing activities | ||
| Purchase of property, plant and equipment | (443) | (300) |
| Interest received | 126 | 486 |
| Payment for acquisition of business, net of cash acquired | (7,235) | (1,113) |
| Purchase of Investments accounted for using the FVTPL | (35,616) | (52,572) |
| Redemption of Investments | 38,090 | 47,932 |
| Investment in fixed deposit | (3,663) | (18,168) |
| Redemption / maturity of fixed deposit | 3,617 | 16,908 |
| Net cash used in investing activities (B) | (5,124) | (6,827) |
| C. Cash flows from financing activities | ||
| Proceeds from fresh issue of equity shares (net of share issue expense) | 53 | 7,327 |
| Interest and finance charges paid | ^ | (103) |
| Payment of lease liabilities | (399) | (318) |
| Dividend Paid | (480) | – |
| Repayment of borrowings | – | (4,031) |
| Net cash generated / (used) in from financing activities ( C ) | (826) | 2,875 |
| Net increase in cash and cash equivalents (A+B+C) | 558 | 467 |
| Cash and cash equivalents at the beginning of the year | 2,410 | 1,886 |
| Effect of exchange differences on translation of foreign currency cash and cash equivalents | 40 | 57 |
| Cash and cash equivalents at the end of the year | 3,008 | 2,410 |
| For the purpose of the statement of cash flow, cash and cash equivalents comprise the following: | ||
| Cash in hand | – | – |
| Balances with banks: – In current accounts | 2,258 | 1,503 |
| Balances with banks: – In deposit accounts | 750 | 907 |
| Total | 3,008 | 2,410 |
| Particulars | Quarter ended 31 March 2026 (Unaudited) | Quarter ended 31 December 2025 (Unaudited) | Quarter ended 31 March 2025 (Unaudited) | Year ended 31 March 2026 (Audited) | Year ended 31 March 2025 (Audited) |
|---|---|---|---|---|---|
| 1. Segment revenue | |||||
| Enterprise Medical Solutions | 2,537 | 2,387 | 2,107 | 9,298 | 8,025 |
| Enterprise Commercial Solutions | 7,193 | 6,689 | 5,222 | 24,605 | 19,348 |
| Others* | 304 | 345 | 227 | 1,202 | 1,020 |
| Total | 10,034 | 9,421 | 7,556 | 35,105 | 28,393 |
| 2. Segment results | |||||
| Enterprise Medical Solutions | 672 | 612 | 585 | 2,435 | 2,081 |
| Enterprise Commercial Solutions | 1,212 | 1,199 | 1,062 | 4,492 | 3,942 |
| Others* | (163) | (55) | (100) | (327) | (329) |
| Total | 1,721 | 1,756 | 1,547 | 6,600 | 5,694 |
| Unallocable expenses | (85) | (161) | (72) | (410) | (351) |
| Depreciation and amortisation expense | (418) | (396) | (207) | (1,264) | (802) |
| Other income (net) | 107 | 194 | 256 | 720 | 1,072 |
| Finance cost | (71) | (46) | (31) | (193) | (220) |
| Exceptional item | (203) | – | – | (203) | – |
| Tax expense | (254) | (318) | (317) | (1,239) | (1,326) |
| Profit after Tax | 797 | 1,029 | 1,176 | 4,011 | 4,067 |
| Sl. No. | Particulars | Quarter ended 31 March 2026 (Unaudited) | Quarter ended 31 December 2025 (Unaudited) | Quarter ended 31 March 2025 (Unaudited) | Year ended 31 March 2026 (Audited) | Year ended 31 March 2025 (Audited) |
|---|---|---|---|---|---|---|
| 1 | Income | |||||
| (a) Revenue from operations | 3,682 | 2,901 | 2,667 | 12,206 | 10,936 | |
| (b) Other income (net) | 61 | 226 | 352 | 783 | 904 | |
| Total income | 3,743 | 3,127 | 3,019 | 12,989 | 11,840 | |
| 2 | Expenses | |||||
| (a) Employee benefits expense | 2,134 | 2,019 | 1,845 | 7,952 | 7,592 | |
| (b) Finance costs | 31 | 18 | 15 | 87 | 62 | |
| (c) Depreciation and amortisation expense | 109 | 95 | 69 | 363 | 262 | |
| (d) Other expenses | 517 | 505 | 426 | 1,773 | 1,539 | |
| Total expenses | 2,791 | 2,637 | 2,355 | 10,175 | 9,455 | |
| 3 | Profit before tax (1-2) | 952 | 490 | 664 | 2,814 | 2,385 |
| 4 | Tax expense | |||||
| – Current tax | 260 | 129 | 174 | 707 | 630 | |
| – Deferred tax | (29) | 13 | (52) | (12) | (58) | |
| Total tax expense | 231 | 142 | 122 | 695 | 572 | |
| 5 | Profit for the period/year (3-4) | 721 | 348 | 542 | 2,119 | 1,813 |
| 6 | Other Comprehensive Income (OCI), net of taxes | |||||
| Items that will not be reclassified subsequently to the statement of profit or loss: | ||||||
| Remeasurement of defined benefit obligation | (1) | 6 | (39) | 41 | (21) | |
| Deferred tax relating to items that will not be reclassified to profit and loss | 1 | (1) | 10 | (10) | 5 | |
| Items that will be reclassified subsequently to profit or loss: | ||||||
| Exchange differences on translating the financial statements of foreign operation | – | – | 5 | – | 3 | |
| Net change in fair value of forward contracts designated as cash flow hedges | (79) | – | – | (79) | – | |
| Deferred tax relating to items that will be classified to profit and loss | 20 | – | – | 20 | – | |
| Total Other Comprehensive (Loss)/Income for the period/year (net of tax) | (59) | 5 | (24) | (28) | (13) | |
| 7 | Total comprehensive income for the period/year (5+6) | 662 | 353 | 518 | 2,091 | 1,800 |
| 8 | Paid-up equity share capital (Face value of ₹ 2 each) | 481 | 480 | 479 | 481 | 479 |
| 9 | Other equity | 20,324 | 18,403 | |||
| 10 | Earning per equity share (face value ₹ 2 each)* | |||||
| (a) Basic (in ₹) | 3.00 | 1.45 | 2.26 | 8.83 | 7.64 | |
| (b) Diluted (in ₹) | 2.98 | 1.44 | 2.25 | 8.78 | 7.59 |
| Particulars | As at 31 March 2026 Audited | As at 31 March 2025 Audited |
|---|---|---|
| A. ASSETS | ||
| I. Non-current assets | ||
| (a |